Business
Sales of Leqembi® totaled 18 billion yen in the third quarter 2025
BioArctic AB's (publ) (STO: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2025, in conjunction with their partner Biogen's third quarter report. In total, sales of JPY 18 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 117.2 million which is an increase of approximately 68 percent compared to the royalty obtained by BioArctic for the third quarter 2024.
About this update from Biogen Inc.
[{"type":"text","content":"STOCKHOLM, Oct. 30, 2025 /PRNewswire/ -- BioArctic AB's (publ) (STO: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2025, in conjunction with their partner Biogen's third quarter report. In total, sales of JPY 18 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 117.2 million which is an increase of approximately 68 percent compared to the royalty obtained by BioArctic for the third quarter 2024. ","length":509,"tagName":"p"},{"type":"text","content":"BioArctic's report for the third quarter 2025 will be published on November 13th, 2025, at 08:00 a.m. CET.","length":110,"tagName":"p"},{"type":"text","content":"This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on October 30, 2025, at 11:00 a.m. CET.","length":263,"tagName":"p"},{"type":"text","content":"For further information, please contact: Oskar Bosson, VP Communications and Investor RelationsE-mail: [email protected]: +46 704 107 180","length":163,"tagName":"p"},{"type":"text","content":"About lecanemab (Leqembi®)","length":26,"tagName":"p"},{"type":"text","content":"Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).","length":245,"tagName":"p"},{"type":"text","content":"Lecanemab is approved in 51 countries including the U.S., Japan, China, and the European Union for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD) and is under regulatory review in 9 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in China, the U.S. and others, and applications have been filed in 9 countries and regions. Leqembi Iqlik™ is approved for subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease in the US. In September 2025...